HK1223112A1 - Anti-tnf-alpha/cxcl10 double-targeting antibody and use thereof - Google Patents
Anti-tnf-alpha/cxcl10 double-targeting antibody and use thereof Download PDFInfo
- Publication number
- HK1223112A1 HK1223112A1 HK16111369.2A HK16111369A HK1223112A1 HK 1223112 A1 HK1223112 A1 HK 1223112A1 HK 16111369 A HK16111369 A HK 16111369A HK 1223112 A1 HK1223112 A1 HK 1223112A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- antibody
- seq
- amino acids
- tnf
- cxcl10
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130057762 | 2013-05-22 | ||
| KR20130057762 | 2013-05-22 | ||
| KR20130057475 | 2013-05-22 | ||
| KR20130057475 | 2013-05-22 | ||
| PCT/KR2014/004579 WO2014189306A1 (ko) | 2013-05-22 | 2014-05-22 | 항 ＴＮＦ-α/ＣＸＣＬ10 이중 타겟 항체 및 그의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1223112A1 true HK1223112A1 (en) | 2017-07-21 |
Family
ID=51933801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16111369.2A HK1223112A1 (en) | 2013-05-22 | 2014-05-22 | Anti-tnf-alpha/cxcl10 double-targeting antibody and use thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10087248B2 (enExample) |
| EP (1) | EP3000827B1 (enExample) |
| JP (1) | JP2016520595A (enExample) |
| KR (1) | KR101671955B1 (enExample) |
| CN (1) | CN105263964A (enExample) |
| AU (1) | AU2014269287B2 (enExample) |
| BR (1) | BR112015029224A2 (enExample) |
| CA (1) | CA2913118A1 (enExample) |
| HK (1) | HK1223112A1 (enExample) |
| PH (1) | PH12015502601A1 (enExample) |
| WO (1) | WO2014189306A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ789594A (en) | 2016-06-20 | 2025-07-25 | Kymab Ltd | Anti-PD-L1 antibodies |
| US20210246227A1 (en) * | 2017-05-31 | 2021-08-12 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
| WO2019197979A1 (en) * | 2018-04-10 | 2019-10-17 | Y-Biologics Inc. | Cell engaging binding molecules |
| US10633458B2 (en) | 2018-04-10 | 2020-04-28 | Y-Biologics Inc. | Cell engaging binding molecules |
| KR102088789B1 (ko) * | 2018-06-20 | 2020-03-13 | 인하대학교 산학협력단 | 항 TNF/IFN scFv-Fc 이중 표적 항체 및 이의 이용 |
| KR102323342B1 (ko) | 2019-04-26 | 2021-11-08 | 주식회사 와이바이오로직스 | IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체 |
| KR102385046B1 (ko) | 2020-08-24 | 2022-04-13 | 에스큐엔지니어링(주) | 드론에 탈부착 점검장치를 이용한 다목적 구조물 검사장치 |
| BR112023020167A2 (pt) * | 2021-03-31 | 2023-12-12 | Univ California | Fusões agente-ligante de ligação biespecífica para a degradação de proteínas alvo |
| KR102357756B1 (ko) | 2021-05-14 | 2022-02-09 | 유한회사 서해항공방제 | 드론을 이용한 유해 조수 및 곤충 방제장치 및 그를 구비하는 드론 |
| CN114432502B (zh) * | 2021-12-31 | 2023-02-03 | 中山大学附属第八医院（深圳福田） | 一种负载op3-4多肽、抗cxcl9抗体的水凝胶及其制备方法与应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103275221B (zh) * | 1996-02-09 | 2016-08-17 | 艾伯维生物技术有限公司 | 结合人TNFα的人抗体 |
| WO2005023201A2 (en) | 2003-09-09 | 2005-03-17 | Medarex, Inc. | Methods for treating rheumatoid arthritis |
| JP2008534508A (ja) | 2005-03-22 | 2008-08-28 | メドスター ヘルス インコーポレイテッド | 心血管疾患を診断および処置するための送達システムおよび方法 |
| CA2608728A1 (en) * | 2005-05-16 | 2006-11-23 | Abbott Biotechnology Ltd. | Use of tnfa inhibitor for treatment of erosive polyarthritis |
| AU2006261357A1 (en) * | 2005-06-17 | 2006-12-28 | Zimmer Spine Austin, Inc. | Improved method of treating degenerative spinal disorders |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| CA2618482C (en) * | 2005-08-19 | 2014-10-07 | Abbott Laboratories | Dual variable domain immunoglobin and uses thereof |
| JP2012228248A (ja) * | 2005-08-19 | 2012-11-22 | Abbott Lab | 二重可変ドメイン免疫グロブリン及びその使用 |
| AR069495A1 (es) | 2007-11-30 | 2010-01-27 | Glaxo Group Ltd | Construcciones de union de antigenos para el tratamiento de cancer o enfermedades inflamatorias (asma, artritis o artrosis) |
| WO2011090762A1 (en) | 2009-12-29 | 2011-07-28 | Emergent Product Development Seattle, Llc | Heterodimer binding proteins and uses thereof |
| ES2682081T3 (es) * | 2011-10-11 | 2018-09-18 | F. Hoffmann-La Roche Ag | Ensamblaje mejorado de anticuerpos biespecíficos |
| KR20130121601A (ko) | 2012-04-27 | 2013-11-06 | 주식회사에이앤알쎄라퓨틱스 | 인간 항 ｃｘｃｌ－１０ 항체 및 이를 포함하는 류마티스 관절염 치료용 조성물 |
-
2014
- 2014-05-22 WO PCT/KR2014/004579 patent/WO2014189306A1/ko not_active Ceased
- 2014-05-22 CA CA2913118A patent/CA2913118A1/en not_active Abandoned
- 2014-05-22 JP JP2016515273A patent/JP2016520595A/ja active Pending
- 2014-05-22 KR KR1020140061598A patent/KR101671955B1/ko active Active
- 2014-05-22 US US14/893,071 patent/US10087248B2/en active Active
- 2014-05-22 CN CN201480029427.2A patent/CN105263964A/zh active Pending
- 2014-05-22 EP EP14801159.6A patent/EP3000827B1/en active Active
- 2014-05-22 HK HK16111369.2A patent/HK1223112A1/en unknown
- 2014-05-22 AU AU2014269287A patent/AU2014269287B2/en not_active Ceased
- 2014-05-22 BR BR112015029224A patent/BR112015029224A2/pt not_active IP Right Cessation
-
2015
- 2015-11-23 PH PH12015502601A patent/PH12015502601A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014189306A1 (ko) | 2014-11-27 |
| US10087248B2 (en) | 2018-10-02 |
| EP3000827B1 (en) | 2020-04-22 |
| EP3000827A1 (en) | 2016-03-30 |
| AU2014269287B2 (en) | 2016-08-25 |
| BR112015029224A2 (pt) | 2017-09-19 |
| JP2016520595A (ja) | 2016-07-14 |
| CA2913118A1 (en) | 2014-11-27 |
| US20160108118A1 (en) | 2016-04-21 |
| WO2014189306A8 (ko) | 2015-12-03 |
| PH12015502601A1 (en) | 2016-02-29 |
| KR101671955B1 (ko) | 2016-11-07 |
| AU2014269287A1 (en) | 2015-12-10 |
| KR20150010919A (ko) | 2015-01-29 |
| EP3000827A4 (en) | 2016-08-24 |
| CN105263964A (zh) | 2016-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3000827B1 (en) | Anti-tnf-alpha/cxcl10 double-targeting antibody and use thereof | |
| JP6883591B2 (ja) | 抗ヒトインターロイキン−１７ａモノクローナル抗体、その製造方法及び使用 | |
| RU2509777C2 (ru) | Анти-mif антитела | |
| JP5289285B2 (ja) | Ｖｅｇｆ−特異的なヒト抗体 | |
| JP2021502407A (ja) | ４−１ｂｂ抗体およびその製造方法と使用 | |
| TW201837056A (zh) | Ｂ７－ｈ３抗體、其抗原結合片段及其醫藥用途 | |
| WO2021023274A1 (zh) | 人源化抗TNFα抗体及其用途 | |
| WO2017198148A1 (zh) | 一种il-13抗体及其制备方法和应用 | |
| EP3178931B1 (en) | Anti-orai1 antibody | |
| CN109776677B (zh) | 一种人源化抗il-13抗体及其制备方法和应用 | |
| EP3689906B1 (en) | Il-5 antibody or antigen binding fragment thereof in medical application | |
| KR102800024B1 (ko) | 항-ｍｙｌ9 항체 | |
| WO2015113494A1 (zh) | 双功能融合蛋白及其制备方法和用途 | |
| KR20250040987A (ko) | 항-아드레노메둘린 비중화 항체, 이의 제조 방법 및 응용 | |
| WO2018006824A1 (zh) | 一种BLyS抗体及其制备方法和应用 | |
| WO2021083248A1 (zh) | 抗tspan8单克隆抗体及其用途 | |
| WO2025223473A1 (zh) | 抗gdf-15抗体及其应用 | |
| EP4238995A1 (en) | Wars-neutralizing antibody and use thereof | |
| WO2025140619A1 (zh) | 包含ccr8抗原结合结构域的多特异性抗体 | |
| WO2024255683A1 (zh) | 抗bdca2抗体 | |
| CN119552247A (zh) | 抗cd25抗体及其医药用途 | |
| CN115572330A (zh) | 一种特异性抗体及其制备方法和应用 | |
| CN114075284A (zh) | Cd47结合分子及其用途 | |
| CN110922483A (zh) | 抗ccr5抗体及其在治疗肿瘤中的应用 | |
| HK40025972B (en) | Il-5 antibody, antigen binding fragment thereof, and medical application therefor |